Live-attenuated Varicella Vaccine
Overview
Authors
Affiliations
This article reviews the history and development of live attenuated varicella vaccine from its early days in Japan to its widespread use throughout the world. The vaccine has proven extremely safe after immunization of as many as 10 million healthy children and adults in the United States alone. The vaccine is also highly immunogenic and offers close to 100% protection from severe chickenpox and 90% protection from illness. It is expected to have a major impact on the epidemiology of varicella and zoster in countries with high vaccine uptake.
Advances in Next-Generation Coronavirus Vaccines in Response to Future Virus Evolution.
Li L, Wei Y, Yang H, Yan J, Li X, Li Z Vaccines (Basel). 2022; 10(12).
PMID: 36560445 PMC: 9785936. DOI: 10.3390/vaccines10122035.
Hong K, Sohn S, Choe Y, Rhie K, Lee J, Han M J Korean Med Sci. 2021; 36(36):e222.
PMID: 34519184 PMC: 8438188. DOI: 10.3346/jkms.2021.36.e222.
Lindahl J, Friman V, Westphal Ladfors S, Hansson S, Andersson R, Jertborn M Acta Paediatr. 2018; 107(12):2185-2192.
PMID: 29706010 PMC: 6282574. DOI: 10.1111/apa.14375.
Dissecting the Molecular Mechanisms of the Tropism of Varicella-Zoster Virus for Human T Cells.
Sen N, Arvin A J Virol. 2016; 90(7):3284-7.
PMID: 26792747 PMC: 4794656. DOI: 10.1128/JVI.03375-14.
Halford W, Puschel R, Rakowski B PLoS One. 2010; 5(8):e12251.
PMID: 20808928 PMC: 2923193. DOI: 10.1371/journal.pone.0012251.